As the parallel existing between MetS and pediatric obesity is well known, the diet indicated among this group of patients must be a balanced one, based on the exclusion of products rich in saturated fats, processed foods, sodium, sugars (which induce an increase in insulin production in the pancreas), carbohydrates or with a high caloric content. A Mediterranean diet (MD) is thus preferred. Additionally, we note the importance of encouraging the practice of physical activity. We recognize the difficulty of obtaining and maintaining these goals both in the pediatric population and in adults, partly due to low motivation (1, 44–46). Therefore, in order to achieve a healthy development of children and to prevent long-term metabolic and cardiovascular diseases, we consider it important to know the basic principles of the Mediterranean diet. Being one of the most intensively studied diets, the Mediterranean food model is centered on high fiber consumption in the form of fruits and vegetables (essential source of vitamins, minerals and antioxidants), the preference for using olive oil as the main source of monounsaturated fats and antioxidants and grain integration, moderate consumption of proteins, especially fish (source of omega-3 fatty acids) and white meat, increased consumption of nuts and legumes (e.g., beans, lentils, chickpeas), limited consumption of sweets and sweetened beverages, adequate hydration with water, regular meals with moderate portions and regular physical activity (47, 48). Currently, the optimal integration of MD into the lifestyle must also take into account the entire process of food production and processing (e.g., the harvesting process), the characteristics of food consumption (e.g., seasonal and local consumption), cooking techniques (extensive use of olive oil with different spices) or eating behaviors (social consumption) (49).

Adherence to such a diet has multiple benefits, among which we note the reduction of obesity, carbohydrate/lipid metabolic disorders and the prevalence of comorbidities associated with pediatric MetS - an aspect certified by the randomized controlled study of 70 teenage girls (50). Also, the current literature notes the relationship between low MD adherence and increased incidence of central obesity, hypertriglyceridemia, and insulin resistance. However, data on the implications of obesity-related genotypes in modulating the relationship MD adherence – obesity – pediatric MetS risk are considered insufficient. Thus, the authors encourage the continuation of research in this field (49).

Another vital aspect of the preference for a MD is attributed to the reduction of chronic systemic inflammation by increasing the amount of antioxidants and healthy fats ingested. Through this mechanism, MD intervenes in regulating lipid homeostasis and reducing the risk of cardiovascular diseases (51, 52). At the same time, MD was correlated with an improvement in insulin sensitivity and a decrease in blood glucose levels, an essential aspect in the prevention and treatment of type 2 diabetes in children and adolescents (47, 53).

In order to be able to adapt and monitor adherence to the Mediterranean dietary changes according to individual needs, the authors have imagined over time several evaluation models. Among these, we mention the KIDMED Mediterranean diet quality index for children and adolescents as a benchmark (54). Cars et al. recognize the indisputable benefits of MD, doubled by avoiding a sedentary lifestyle in increasing the quality of life of children. Next, the authors discover incompletely studied directions. In this sense, they support the need to direct future efforts toward exploring the impact of MD on cognitive functions, academic performance and mental health, emphasizing the importance of establishing healthy eating habits early in life (51).

Among all food constituents, the most important contribution in pediatric MetS, insulin resistance and waist-to-hip ratio was played by solid fibers that interact with adipose balance by slowing gastric emptying and promoting satiety, Ventura et al. emphasizing that, 1.1 g of fiber (one apple) represents the difference in value between the diet of children without symptoms of MetS and that of subjects manifesting this condition (55).

Thus, the weight loss obtained with the help of non-surgical means has been proven to have a beneficial effect on systemic inflammation, arterial hypertension, dyslipidemia and insulin resistance, although it is difficult to know exactly the percentage of weight loss required for each child depending on age, gender and stage of puberty (44, 56). For the purpose of easier orientation, the dietary treatment of pediatric MetS has been subdivided into four steps (Figure 2).

It seems that the relationship between pediatric MetS and obesity - a condition whose incidence is predominantly dictated by eating habits and daily physical activity - is a bidirectional one. The latter exerts both systemic effects, potentiating the incidence of pediatric MetS and the main comorbidities that make it up, as well as individual effects on each individual component (57, 58). In support of the correlation stated above, we mention the results of a randomized study carried out by Velázquez-López et al., which objectified the different impact of the two types of diet (Mediterranean versus fast-food type) on BMI, blood glucose level, triglycerides and pediatric MetS components. The authors note an improvement in these variables after 16 weeks of a diet rich in dietary fiber, omega 9 fatty acids, proteins, zinc, selenium, vitamin E and flavonoids. Additionally, an increase in HDL-cholesterol is observed (59). Also, Pedrosa et al. identifies a decrease in the prevalence of MetS by 1.6% among overweight/obese children aged between 7 and 9 who followed a physical and nutritional counseling program during 1 year. In the same category, the authors reiterate the improvement of the previously specified parameters (60).

Diet also modulates inflammatory activity. Dietary intake of fats and antioxidants (vitamin E, C and beta-carotene) was noted as an important factor in the dynamics of C-reactive protein (CRP), interleukin 6 (IL-6), leptin and retinol-binding protein levels (RBP) 4. No similar findings were issued in the case of tumor necrosis factor (TNF-alpha) (50, 61). Besides these, the level of vitamin B12 correlates inversely proportionally with the risk of MetS in children, while the folate value is directly proportionally correlated. Vitamin B6 does not seem to influence this pathology (62). Another important micronutrient in the pathogenesis of pediatric MetS, type 2 diabetes and obesity is magnesium. However, its deficit is underestimated, partly due to the uneven distribution between the plasma and the intracellular environment, an aspect that can vitiate its dosage. We also draw attention to the calcium–magnesium interrelationship, crucial both in obesity and pediatric MetS, as well as in insulin homeostasis (correlated inversely proportionally with the value of magnesium) (63).

Despite the multiple advantages stated previously (e.g., improving insulin sensitivity, reducing body weight, increasing the intake of antioxidants and fibers, improving the lipid profile or the blood pressure level) it must be recognized that the diets frequently used in the management of MetS in children can be burdened by various limitations (64, 65). Among these we note aspects such as the risk of deficiencies in fiber, vitamins from the B complex and antioxidants, found in the case of diets low in carbohydrates. This can also predispose to an unbalanced diet that will subsequently increase the risk of dyslipidemia or cardiovascular diseases. In parallel with this, diets based on fat reduction can potentiate deficiencies of fat-soluble vitamins (A, D, E, and K) and essential fatty acids. These biomolecules are essential for the optimal neurological and immune development of children. At the same time, low fat intake can predispose to an increased consumption of refined carbohydrates, which aggravates imbalances in carbohydrate metabolism (12, 66–68). Finally, regarding the Mediterranean diet, we would like to draw attention to the fact that, although it is considered well tolerated, accompanied by low risks, it can be difficult to maintain due to cultural considerations or various restrictive culinary preferences of children. Also, monitoring caloric intake is important because excessive consumption of fats, even healthy ones, can stimulate weight gain. Similarly, the DASH diet can be assimilated as a diet that is difficult to follow and calibrated so as not to reduce the intake of healthy fats and proteins below the optimal level, essential elements for the normal growth and development of children (69, 70).

Progressive, moderate, non-competitive physical activity (e.g., using a bicycle for transportation, walking, jogging, and swimming, joining sports clubs) is inversely correlated with the risk of developing pediatric MetS. It is thus recommended a minimum of 30–60 min/day for children older than 5 years, with proven importance in increasing basal metabolism and maintaining the balance between ingested energy and consumed energy, reducing BMI and waist circumference (more pronounced in the case of boys), of the substrate necessary for lipogenesis, insulin resistance and systemic inflammation, the inversion of the HDL/LDL and triglyceride ratio and the improvement of endothelial function in parallel with the improvement of blood pressure. However, less than 30% (between 20–80%) of patients manage to reach this target (1, 44, 56). It is important to mention that exercises that cause increased or repeated pressure on the joints of the legs or hips should be avoided in the case of children with severe obesity (44).

With regard to the triad of fats — pediatric MetS — physically activated, it seems that the first ones show a tighter correlation, objectifying the continuation of mutual modulation despite the practice of physical activity. This particularity was not confirmed in the fitness - pediatric MetS correlation. In this situation, the relationship becomes insignificant after controlling for obesity (71). In this sense, we rather emphasize the importance of practicing physical activity for preventive purposes, for modulating the oxidation of the carbohydrate substrate (important in the Apoprotein B-Apoprotein A1 balance) and lipids, maintaining weight in optimal ranges and regulating insulin sensitivity through the influence exerted on proteins and receptors responsible for glucose transport (GLUT4). Although it is unanimously recognized that the two components - diet and sport - act partially synergistically, the difference between them consists in the impact brought by physical activity on muscle mass (72–75). Regarding the type of physical activity practiced, it is difficult to delimit the benefit brought by aerobic versus resistance exercises, the two addressing similar mechanisms such as the promotion of angiogenesis at the muscle level, the increase of blood flow, the stimulation of GLUT and adrenergic receptors (alpha and beta) and the regulation of carbohydrate and lipid metabolism. Their combination is therefore an optimal option (74, 76). However, the ratio between the two types of physical activities is not unanimously recognized. His reports vary in the literature between the practice of both equally and the predominance of aerobic activity. Currently, it is postulated that the preference for a certain aerobic/resistance ratio must vary depending on the severity of the symptoms, the targeted objectives (weight loss and improvement of cardiovascular capacity versus increase of muscle mass and improvement of metabolic rate) and the physical condition of each child (76–78). Another effect of resistance physical activity is represented by the influence of the intestinal microbiome, the structure in a fine balance that imprints both the internal homeostasis, as well as the therapeutic course of numerous pathologies, among which we define pediatric MetS (79).

The intestinal microbiome represents a biosystem made up of trillions of micro-organisms (bacteria, viruses and fungi) that is in a perpetual evolution regarding the diversity and abundance of bacterial genera from the intrauterine environment until the age of senescence (80). Together with the vital organs (e.g., heart, lung, kidney, skin) it forms numerous links whose disturbances impact the homeostasis of the internal environment at various levels (e.g., inflammatory, atopic, autoimmune) (81–89). The current medical literature notes that the alteration of this microenvironment produced by a diet rich in fats, in favor of fibers, is therefore called “intestinal dysbiosis.” Under the umbrella of this definition, we find the abundance of harmful bacterial species (Enterobacteriaceae, Staphylococcus and Clostridium perfringens) at the expense of beneficial ones (Lactobacillus, Bifidobacterium), a balance that influences numerous pathologies both in the sphere of the nervous system and the digestive system, as well as among those that make up pediatric MetS (e.g., obesity, hypertension, type 2 diabetes) (90–93). It is also reiterated the increased risk of colonization with pro-inflammatory or entero-toxic Escherichia Coli in the case of diets rich in fats and sugars (93).

In the pathophysiology of intestinal dysbiosis, a key role is played by short-chain fatty acids (acetate, propionate, butyrate) resulting from fermentation processes and which, in addition to being a powerful metabolic and defense source for epithelial cells, regulate the production of YY peptides and GLP-1 with a role in modulating food intake and the feeling of hunger, but also insulin production and sensitization to it. Added to these are the influence of molecular models associated with pathogens, bile acids, branched chain amino acids and colonic gasses (90).

In the light of these findings, the involvement of the modulation of the human microbiome in the prevention and treatment of pediatric MetS-related disorders is self-evident. This can be achieved with the help of prebiotics from food sources such as asparagus, garlic, leeks, onions, bananas, chicory, wheat bran, and barley. Prebiotics have a role in favoring the preferential growth of commensal bacterial strains. Other means used are represented by probiotics (live microorganisms -e.g., bacteria-, administered exogenously, which contribute to the balance of the intestinal microbiota and the optimal functioning of the digestive and immune systems) or symbiotics (mixtures of prebiotics and probiotics). Although they show heterogeneous results depending on the strain used, the dose, the treatment period and the individual characteristics of the patient at the beginning of the treatment, have proven effective in restoring the intestinal barrier, regulating metabolic parameters, body fat, serum glucose, inflammation and biological (transaminases) and histological characteristics of liver damage (83, 94–97). Although studies among pediatric patients are not as popular and easy as those that include adults, the data in the literature still note the benefit of Lactobacillus administration in the affected population/with risk factors, with the reversal of the ratio of harmful bacteria/beneficial bacteria and the increase in the level of acids short chain fats (90). A similar effect was also proven in the study of supplementation with Bifidobacterium, in murine models. In this situation, the reduction of intestinal inflammation and the improvement of metabolic imbalances were observed (98, 99). The therapeutic hypothesis was also certified by Pan et al., with the help of a meta-analysis. The authors add to the above the harmful impact of the acidic environment created in the intestine due to the administration of prebiotics on the species of Clostridium perfringens and Escherichia Coli (90).

Much more modern, but in the research stage in adults, fecal matter transplantation represents another short-term therapeutic option aimed at the intestinal microbiota. The current literature recognizes favorable results 6 weeks after implementation in terms of peripheral sensitivity to insulin. However, no effects were observed on fasting blood glucose, hepatic gluconeogenesis, BMI, or lipid profile. At the same time, an increase in Ruminococcus bromii and Roseburia intestinalism, bacterial species involved in the degradation of fibers and the production of short-chain fatty acids, was observed (100). In pediatric practice, it was introduced in 2010, being used in Clostridium difficile infection with minor adverse effects - bloating, diarrhea, constipation, abdominal pain, old age or transient fever. Major complications rarely occur, among which we mention aspiration pneumonia in the case of delivery techniques through the upper gastrointestinal floor. Other diseases in which modulation of the intestinal microbiota was practiced for therapeutic purposes were inflammatory bowel diseases, irritable bowel syndrome, refractory diarrhea, neurological diseases (Parkinson’s disease) and autism spectrum disorders (101).

The most important parameters influencing the development and course of MetS in the pediatric population, according to Hirschler et al., seem to be obesity and insulin resistance. The observation was reinforced by the results of a cross-sectional study on 1,009 children, aged between 6 and 14, attending elementary schools in Buenos Aires, Argentina, between April and September 2007 (102). The same author goes further in the study of the impact played by body mass in dictating the subsequent predisposition to comorbidities, reiterating the relationship between increased birth weight and the development of MetS and overweight/obesity in childhood. In contrast, low birth weight has no association with these (103). Obesity is assessed using the BMI Z-score, its increase by one point doubling the prevalence of pediatric MetS. Thus, Sen et al. emphasizes the importance of screening for MetS among children with a BMI Z-score > 2, with the aim of increasing early diagnosis and treatment (104). Also, an important role in optimal management is attributed to dietary modulation and counteracting the pro-oxidative status specific to the pathology (105).

The pharmacological therapy used in obesity is reduced in pediatric practice, partly due to the incomplete research of the products, currently only Orlestin is recommended - a drug that inhibits intestinal lipase, thus reducing the level of triglycerides, cholesterol and body weight by approximately 3%/month. It is approved among teenagers over 12 years old, presenting limited adverse effects such as steatorrhea, abdominal pain or a feeling of urgency to defecate. It is also burdened by the risk of affecting absorption through the interaction with fat-soluble vitamins. Other substances used are Sibutramine and catecholaminergic agents – diethylpropiona, fenproporex and mazindol (44, 45, 56, 106). The clinician’s choice of one of the previously mentioned drugs is dictated by the patient’s associated symptomatology. Thus, Orlestin is used in the case of high-fat diets, not before excluding severe gastrointestinal disorders. Sibutramine, in a dose of 10–15 mg, is indicated in the case of facing the lack of satiety, over the age of 16. Finally, catecholaminergic substances are preferred when pediatric MetS appears in association with attention deficit. There are also other drugs with anti-obesity effects but with restrictions regarding administration due to side effects and contraindications in certain pathologies. Among these we mention Topiramate (anticonvulsant, a history of kidney stones must be excluded), Bupropion (contraindicated in epilepsy) and Fluoxetine (selective serotonin reuptake inhibitor, not administered in bipolar disorders/epilepsy) (56, 106). It is recommended to stop the anti-obesity treatment if it did not have the effect of >4% decrease in BMI or Z-score after 12 weeks of administration at the maximum dose (45).

Metformin, the orally administered representative of the Biguanide class, is a hepatic modulator for insulin, inhibiting gluconeogenesis and thus positively impacting BMI, cholesterolemia and LDL-cholesterol level. At the same time, it is noted that it exerts cardioprotective effects. Thus, it represents a therapeutic option proven to be effective among adolescents, at a dose of 2 g/day (45, 56, 107). The indirect effects of Metformin are obtained by stimulating glucagon-like peptide 1 (GLP-1) agonists. Among the side effects we mention the digestive damage objectified by nausea, bloating, diarrhea or flatulence, vitamin B12 deficiency, lactic acidosis (encountered with the ad-ministration of the substance among patients with renal failure), cardiac damage (congestive heart failure, peripheral perfusion damage), pulmonary (hypoxia) and hepatic (106).

Alternative therapeutic lines seem to include Octreotide and Topiramate (0.5–22 mg). The first one targets pancreatic insulin secretion producing its suppression, with the consequent decrease in fat mass (up to 43% when associated with life-style changes) and the reduction of acanthosis nigricans. However, it is burdened by side effects such as gallstones, hypothyroidism, diabetes and impairment of cardiac function. Consequently, it is important to specify that the two substances are recommended to be used with caution, only in special situations and under careful monitoring (106).

Bariatric surgery is another therapeutic method used among adolescents who meet the criteria. Currently, these include a BMI over 35 kg/m2 accompanied by severe comorbidities such as type 2 diabetes, moderate/severe sleep apnea, liver fibrosis, brain tumors or disabling orthopedic conditions or over 40 kg/m2 together with mild comorbidities such as dyslipidemia, arterial hypertension, mild sleep apnea, steatohepatitis (44). Regarding the surgical techniques, the most often used is the vertical gastrectomy due to the low postoperative complications and the efficiency in weight loss. More recently, modern techniques such as the intragastric balloon or percutaneous gastrostomy are coming to the attention of researchers and medical practitioners, although the data on the benefit and safety of the practice in the pediatric population are insufficient (45). Bariatric surgery can induce metabolic disorders such as malnutrition, loss of bone mass, hyposideremia, hypocalcemia or vitamin deficiencies (A, D, E, K, B12) (106).

The therapy of insulin resistance (IR/metabolic syndrome X) encountered in pediatric MetS remains open to study. The condition is mainly defined by fasting hyperinsulinemia, decreased glucose tolerance, hypertension and dyslipidemia. Additionally, microalbuminuria, the inflammatory syndrome, but also the disruption of essential fatty acid metabolism can be associated (108, 109). Of all these, the most challenging is maintaining glycemic values between optimal levels. This is mainly due to multiple interactions with exogenous and endogenous factors (e.g., the recent COVID-19 pan-demic) (110). The administration of Metformin (in an initial dose of ½ of the adult dose, later increasing to 2/3 of the dose) or other pharmacological products is controversial, as IR has proven to be mostly transient. Less than 2% of subjects develop type 2 diabetes within 5 years. However, when it is installed, in addition to initiating a healthy lifestyle, the pharmacological component is represented by Metformin, Sulfonylurea and Insulin - alone or in combination, depending on the severity of the hyperglycemia, the HbA1c level and the presence/absence of ketosis and ketoacidosis. It should also be taken into account the need to monitor glycemic values and adapt therapeutic doses after correcting the basal glycemia (ideally with the help of the 8-point glycemic profile) (44, 56, 111).

The period of rest (sleep) has proven to be important both in the optimal growth and development of children, as well as in the modulation of insulin sensitivity. A rest period of 8 to 11 h is thus recommended, limiting exposure to screens (blue light) to less than 2 h/day (44). If we still consider the use of pharmacological therapy, it is vital to know certain principles regarding antidiabetics. Among these, we mention the fact that Metformin decreases the hepatic production of glucose, increases peripheral uptake and improves insulin resistance, still requiring caution in the case of teenagers due to its ability to induce ovulation, which can lead to an unwanted pregnancy. Sulfonylurea, administered in a dose of 2/3 of the dose recommended for adults, stimulates the increase of basal and postprandial insulin, with the risk of hypoglycemia. Last but not least, Insulin used in the form of medium- or long-acting analogs corrects blood sugar, reduces glucosuria and can induce hypoglycemia or weight gain (56). Other therapeutic options used in adults, but without sufficient data in children, are sodium-glucose transporter 2 (SGLT2) and dipeptyl-peptidase 4 (DPP4) inhibitors (45).

Lipid balance disturbances are defined as a decrease in HDL, with an increase in triglycerides and maintaining LDL in relatively normal values. Similar to the majority of components that make up pediatric MetS, in their treatment a central role is played by changing the diet with the aim of reducing cardiovascular risks. Note the decrease in LDL and total cholesterol obtained by the combination of reducing dietary fat to 25–30% of daily caloric intake, saturated fat to less than 10% and cholesterol intake to less than 300 mg/day. Diet modulation is preferred over pharmacological therapy with statins, bile salt chelators and cholesterol absorption inhibitors, considered reserved for severe cases or non-responsive to dietary measures (44, 112, 113). Other non-pharmacological therapeutic means are represented by capsules based on pasta oil, administered in a dose of 2 g/day (112).

The addition of the pharmacological component in the therapy of dyslipidemias is recommended to be done after the age of 8 years, in cases with LDL cholesterol ≥190 mg/dL or ≥ 160 mg/dL doubled by family risk factors such as early cardiovascular dis-eases or ≥ 130 mg/dL in the presence of diabetes. Pharmacological treatment under the age of 8 is reserved for cases with LDL cholesterol ≥500 mg/dL (45, 106). Worthy of emphasis is the escalation of the triglyceride value above the threshold of 500–700 mg/dL, at which level the institution of treatment is imperatively necessary due to the increased risk of pancreatitis (112, 114).

From a medicinal point of view, the first therapeutic lines are represented by cholestyramine (resin lacking intestinal absorption, with side effects on the absorption of fat-soluble vitamins and intestinal transit), colestipol, Ezetimibe (cholesterol absorption blocker by acting on the Niemann-Pick C1 protein -like 1) and statins. The side effects noted were similar to adult administration, without disturbing growth and cognitive and sexual development. Fibrate and nicotinic acid have conflicting recommendations regarding administration to children (44, 56, 106, 114). The most potent statins in pediatric treatment proved to be Rosuvastatin, followed by Atorvastatin, due to the prolonged half-life. About the two, it should be known that they can present numerous drug interactions (due to the use of the CYP3A4 substrate), but also side effects such as headaches, dizziness, myalgias and gastrointestinal symptoms (44). Statins produce a reduction of LDL by 30–40% and the risk of atherosclerosis (by reducing the intimal thickness at the level of the carotid vessels), consequently having an impact on the morbidity and mortality induced by cardiovascular diseases. The therapy should be initiated mainly in children older than 8 years to avoid the risk of affecting growth and sexual maturation. The dose used must be small, titrated according to the LDL value and carefully monitored in terms of hepato-renal function (stopping is recommended when liver enzymes exceed 3 times the normal value or creatine kinase exceeds 5 times the normal value) and muscle symptoms - skeletal (myalgia, muscle weakness) (106, 114, 115).

The modern therapies, newly introduced in the therapeutic schemes of dyslipidemias, target cholesterol ester transfer protein inhibitors (Torcetrapib) and Colesevelam (106).

At the pediatric age, blood pressure assessment is done with the help of reporting the child’s value to specific percentiles for age, gender and height. Thus, a normal blood pressure value is defined as the systolic and diastolic pressure value below the 90th percentile for age, gender and height. Furthermore, current guidelines define “prehypertension” as systolic and diastolic blood pressure values greater than the 90th percentile, but less than the 95th percentile for age, gender, and height. Finally, hypertension in pediatrics is considered when the systolic and diastolic values exceed the 95th percentile for age, gender and height (116, 117). Blood pressure imprints the risk of developing pediatric MetS and cardiovascular mortality, along with obesity, increased insulin resistance, hyperinsulinemia, dyslipidemia, chronic inflammation or pro-oxidative status. Thus, a bidirectional relationship between the two entities takes shape. This is influenced, during childhood, by aspects such as practicing physical activity, a diet rich in fruits, vegetables, olive oil (source of polyphenols) and low in sodium. These variables can also be addressed later as the first line of therapy, preceding the introduction of pharmacological substances such as angiotensin-converting enzyme inhibitors - ACEI, thiazide diuretics, calcium channel blockers - CCB or angiotensin receptor blockers - ARB or in combination with them in order to obtain a maximum therapeutic effect (44, 45, 116, 118). In addition to the secondary etiology of hypertension in children (e.g., renal, endocrinological, cardiovascular, pharmacological, obstructive sleep apnea or neoplasia) are also its primary causes (e.g., environmental factors, family history, lifestyle). Also, genetic or prenatal factors (e.g., low birth weight, intrauterine growth restrictions and exposure to maternal smoking during pregnancy) are variables that can negatively impact the prevalence of hypertension in children. Finally, we do not omit the transient causes of hypertension such as fever, acute pain, stress or certain infections (119, 120). Correlations were also observed between the use of antihypertensive treatment in adolescents and regression in the size of the left ventricle, but without improvement in heart rate - rather correlated with visceral obesity that modulates the activity of the sympathetic nervous system (121).

Thus, cardiovascular prevention is an important mechanism in reducing associated morbidity and mortality. This can be done on several levels, the most important of which is primary prevention (preventing the appearance of risk factors for cardiovascular diseases before they develop) and primary (preventing the appearance of cardiovascular diseases in people who already have risk factors). If the first focuses on educating young people about the importance of a balanced diet, regular physical activity, avoiding smoking and limiting alcohol consumption, primary prevention involves monitoring and managing known risk factors through lifestyle changes and the use of pharmacological therapy to reduces cardiovascular risk (119, 122).

In the pre-hypertension phase, it is recommended to practice a healthy life-style, with the promotion of weight loss. For this purpose, a high blood pressure control diet (DASH) is imagined that follows the principles stated above — high intake of whole grains, vegetables, fruits, nuts, legumes, doubled by a moderate intake of low-fat and low-fat dairy products of red meat, sugary drinks and sodium. In the later phases, it is recommended to introduce individualized drug therapy depending on the blood pressure values (123, 124). Weight loss, objectified with the help of an approximately 10% lower BMI, leads to a reduction in blood pressure between 8 and 12 mmHg. Similar results were recorded in the case of practicing regular physical activity for 3–6 months (118). The pharmacological products used to modulate blood pressure must be carefully chosen so as not to interfere with insulin resistance, weight gain (e.g., thiazide diuretics) or glucose tolerance (e.g., beta-blockers). It is therefore understandable the importance of knowing the mechanisms of action, side effects and possible contraindications (56). Initial monotherapy is recommended, with titration of doses every 2–4 weeks and the association of another antihypertensive (e.g., thiazide diuretic, ACEI or ARB) if blood pressure control is not achieved (BP < 90th percentile) or in order to increase adherence, respectively to decrease the cost (45).

In pediatric practice, the following substances are approved, used in standard pediatric doses (Table 3):

The poor response of African Americans to ACEI is known, therefore, in their case, the use of a thiazide diuretic or a calcium channel blocker is recommended in the initial therapy (45).

Similar to the other comorbidities present in the pediatric MetS, the therapeutic market targeting arterial hypertension is constantly developing, the newest products coming into focus being endothelin receptor antagonists (Darusentan) and renin inhibitors (Aliskiren) (106).

Liver damage is also a constituent pathology of MetS in children. Until recently, liver damage following the excessive accumulation of fats from a non-alcoholic cause was called NAFLD. This varies from steatosis to steatohepatitis, progressing over time to fibrosis, cirrhosis or even liver failure. The diagnosis in children is mostly one of exclusion, made by excluding the history of chronic alcohol consumption, as well as viral infections, genetic diseases, medications and other metabolic disorders. Confirmation of the diagnosis is made with the help of imaging methods (ultrasound, MRI) or liver biopsy. Recently, it was proposed to change the terminology from NAFLD to MAFLD. This involves recognizing the direct link between fat accumulation in the liver and metabolic dysfunctions. Consequently, in addition to imaging and histopathological diagnostic methods, we find the need to objectify metabolic dysfunctions adapted to age (increased BMI, type 2 diabetes, insulin resistance, dyslipidemia, hypertension or metabolic syndrome) (125, 126). Due to the variation in diagnostic criteria between the two entities, Xing et al. states that the MAFLD criteria can identify more obese children than the NAFLD criteria. The authors estimate that approximately 19% of children with NAFLD do not have MAFLD, a percentage influenced by the secondary causes of steatosis, not covered by the secondary terminology (127). However, MAFLD is considered superior for reducing stigma, risk of hepatic and extrahepatic mortality, disease associations, and for screening high-risk individuals (126).

Mann et al. underlines, with the help of a meta-analysis that included 21 randomized controlled trials, the heterogeneity of the therapeutic means used in NAFLD. This aspect is partly due to the reporting of the effectiveness of the therapy with the help of liver markers and not histological aspects (the two criteria being met only in the case of antioxidants) (128). Due to the close connection with increased body weight and dyslipidemia, the main component of the treatment is the association between weight loss by approaching a healthy lifestyle (previously described) or resorting to bariatric surgery when there are criteria for this. It is mentioned here that rapid weight loss can worsen fibrosis and steatosis. The other strategies targeting the associated physiopathological mechanisms such as Lactobacillus-based probiotics, N-acetylcysteine, nuclear receptor agonists (Pioglitazone), GLP-1 agonists (Liraglutide), DDP-4 inhibitors (Sitagliptin), omega-3 fatty acids (docosahexaenoic acid) or bile acids (obeticholic acid) and vitamin E, with/without vitamin D in cases of deficiency remain under research (40, 44, 45, 129–132). Uncertain effects seem to appear also in the case of Metformin through the reduction of alanine amino-transferase (ALT) and the positive modulation of histological dynamics (45, 132). Antifibrotic agents must be added to these because, despite the possible clinical-biological reversal of the steatohepatitis process, patients may still present with fibrosis (129).

In pediatric MetS therapy, possible drug interactions must also be taken into account. Data from the literature of recent years show an increase in its incidence among patients, especially children, under treatment with second-generation antipsychotics (Clozapine, Olanzapine, and Risperidone) for neuropsychiatric disorders - e.g., behavioral disorders or schizophrenia. The clinical manifestations seem to follow each other in a vicious circle, the starting point of which is represented by the imbalance of appetite as a result of the vicious integration of the regulation signals at the level of the arcuate nucleus or the disturbance of the intestinal microbiota. From a therapeutic point of view, the effectiveness of obtaining control of the symptoms with the help of the means stated above remains controversial. However, food polyphenols are recommended in the control of obesity, inflammation and insulin resistance (133–136). Early recognition of MetS, especially among children who receive antipsychotic treatment for long periods, is therefore an essential component in clinical practice. The screening targets the same lines as in the classic syndrome, namely the measurement of body weight, waist circumference, lipid profile and the value of blood glucose and insulin after digestive rest (fasting) (137).

The particular aspects of the evolutionary course in pediatric MetS, which must be considered by the clinician for the purpose of early diagnosis and optimal treatment, include its entanglement with other pathologies/medical interventions such as hematopoietic stem cell transplantation, respectively liver. In this situation, the pathology is precipitated as a consequence of the existence of risk factors such as non-alcoholic fatty liver, bone or renal complications, but also the use of immunotherapy, corticotherapy or calcineurin inhibitors (138). It seems that the risk of the occurrence of the comorbidities that make up pediatric MetS is higher starting with the early post-transplant period and spreads over 5 to 10 years after it, having an undulating, individual incidence over time (139). However, the theory remains controversial, Kosola et al. reporting, through a cross-sectional study, a prevalence of pediatric MetS components similar to that found in the general population, namely 20% for overweight, 24% for hypertension, 14% for fasting hyperglycemia, 9% for hypertriglyceridemia and 23% for lowering of HDL-cholesterol. The authors do not highlight a significant correlation with the use of immunosuppression (140). Regarding the metabolic consequences of stem cell transplantation, Paris et al. recorded a prevalence of pediatric MetS of 32%, significantly higher than the healthy population, doubled by the strong association between it and the use of corticotherapy (141).

At the same time, in agreement with the above, knowledge and practical integration of the principles of the Mediterranean diet must represent a desire of modern medicine. In this sense, Table 4 shows the most used foods, their recommended frequency, the constituent nutritional principles, as well as the biological functions performed.

In conclusion, MetS represents a touchstone for the clinician, especially at the pediatric age, partly due to the entanglement of multiple physiopathological processes that promote and potentiate each other. The optimal knowledge of preventive and therapeutic measures is therefore vital in the evolutionary course of affected children, with resonance both from a psychological and social point of view, as well as in the quality of life of the future adult. The narrative exposition fulfilled its purpose of creating a schematic description of the general characteristics related to pediatric MetS, the location of the pathology in the current epidemiological context, its diagnosis, pathogenic mechanisms underlying the development, the main risk factors encountered and the way in which they can be modulated for a beneficial purpose. The central point of interest was the display of the main directions used in the approach to the patient with pediatric MetS, starting from lifestyle changes and culminating with pharmacotherapy aimed at the various associated comorbidities - obesity, dyslipidemia, hypertension, changes in insulin metabolism or non-fatty liver -alcoholic. For this purpose, the main pharmacological products approved or in the process of being approved in pediatrics were presented, doubled by doses, mechanisms of action, clinical results, but also frequent adverse effects. The novelty brought into discussion is the approach to the fecal microbiota (probiotics, transplant) in modulating the metabolic imbalance and emphasizing the additional risk of the use of antipsychotics in inducing disturbances. Attention was also drawn to the implications of stem cell or liver transplantation in disrupting the body’s homeostasis, especially the pathology targeted in this study. Therefore, pediatric MetS can be considered a complex syndrome whose knowledge and prevention are a pillar in the optimal development of society. For this purpose, we draw attention to the need to implement standardized screening programs, to popularize the benefits of a healthy lifestyle, but also to form “attack” protocols at the level of each region with the aim of eliminating the variability of therapeutic results induced by cultural and racial differences.